Abbott goes after J&J over Simponi

The WSJ notes Abbott is going after J&J and writes:

Abbott, of Abbott Park, Ill., markets Humira, a treatment for rheumatoid arthritis and other conditions, which competes with J&J's Remicade. J&J's follow-up to Remicade, Simponi, was approved by the U.S. Food and Drug Administration on April 24. Schering-Plough Corp. (SGP) markets both Remicade and Simponi outside the U.S. in a partnership with J&J, New Brunswick, N.J.